source
- Endpoints Weekly previews ASCO coverage, discusses AI in research and shifting immunotherapy strategiesThe weekly newsletter returns with a team of reporters stationed in Chicago for the upcoming ASCO meeting. It promises on‑the‑ground insights from the conference. One focus will be the role of art…
- Bristol Myers reports 52% reduction in progression risk for next-gen multiple myeloma drug in Phase 3 trialBristol Myers Squibb said its next-generation multiple myeloma therapy, positioned as a successor to Pomalyst, lowered the risk of disease progression or death by 52% when added to a standard combi…